Key facts
- This page summarizes William D. Young's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Apr 2022, 21:34.
William D. Young - 26 Apr 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)
- Reporting relationship
- Director
- Issuer ticker
- TBPH
- Reported as of
- 26 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Apr 2022, 21:34:22 UTC
- Prior SEC filing
- 09 Jun 2021
- Next SEC filing
- 27 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett A. Grimaud, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William D. Young filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 28 Apr 2022.
Change
- Previous filing in this sequence was filed on 09 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBPH
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +9,852
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 78,010
- Date
- 26 Apr 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TBPH
transaction
Derivative
Share Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +28,000
- Change %
- Price
- $0.000000
- Shares after
- 28,000
- Date
- 26 Apr 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 28,000
- Exercise price
- $10.15
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.